Fig. 1



Assessed for eligibility (n=195)
Screen failures (n=75)
• Laboratory results (n=54)
• Inclusion/exclusion (n=17)
• Withdrawal by participant (n=2)
• Other (n=2)
Randomized (n=120)
Placebo (n=40)
Obicetrapib 5 mg (n=40)
Obicetrapib 10 mg (n=40)
Discontinued treatment: AE (n=1)[1]
Discontinued treatment (n=0)
Discontinued treatment (n=0)
Discontinued study early: lost to follow-up (n=2) protocol deviation (n=1) other (n=1)
Discontinued study early: subject withdrawal (n=1)
Discontinued study early (n=0)
Analysis populations
ITT population (n=40)
ITT population (n=40)
ITT population (n=40)
mITT population (n=40)
mITT population (n=40)
mITT population (n=40)
Safety population (n=40)
Safety population (n=40)
Safety population (n=40)
PP population (n=39)[2]
PP population (n=39)[2]
PP population (n=39)[2]
PK population (n=40)
PK population (n=40)
PK population (n=40)

Fig. 2a




Fig. 2b




Fig. 2c

